Novel and emerging medical radionuclides
Villigen, 23.9.2021 - PRISMAP – The European medical radionuclides programme sets out to substantially change the European landscape for novel and emerging medical radionuclides. Nuclear therapy and molecular imaging are widely used at hospitals for new promising medical procedures. They can drastically improve the outcome for many medical conditions and in particular enable the treatment of disseminated cancer. However, its effective development has long been limited by the difficult access to radionuclides, which are not yet commercially available. With PRISMAP – the European medical radionuclides programme – this is about to change. The Paul Scherrer Institute PSI being part of PRISMAP is one of the providers of radionuclides.